Summarized by Masters of Longevity from Longevity Technology.
Continuous AMVUTTRA treatment was associated with lower mortality and recurrent cardiovascular events.
Key Takeaways
- Monotherapy group had about 48% lower composite risk.
- Full cohort showed approximately 41% fewer recurrent events.
- Study is observational five-year follow-up and noncausal.
